Non-animal Alternative Testing Market - By Product (Organs-on-chip, Tissue Line), Method (Ex vivo, Computer Modelling), Technology (Cell Culture, High Throughput), Application (Infectious, Immunological), End-use (Biotech Companies, CRO)- Global Forecast to 2032

Non-animal Alternative Testing Market Size

Non-Animal Alternative Testing Market size was valued at USD 1.7 billion in 2022 and will progress tremendously to reach over USD 4.5 billion by 2032 at 10.3% CAGR. The high market growth is owing to the rising emphasis on animal welfare as part of global sustainable development goals.
 

While animal models are critical to biomedical research for drug and treatment developments, research agencies are encouraging the adoption of complementary approaches or alternatives to animal testing. Additionally, adoption of the 3R principles (replacement, reduction, and refinement) by both regulatory bodies and end-use industries, specifically in the field of pharmaceuticals is expected to drive the market for non-animal alternative testing during projection period.
 

Non-animal alternative testing are methods for replacing animals used in experiments such as clinical studies for drug development with algorithms and computational programs in order to avoid animal cruelty and maintain ethical practices while achieving maximum accuracy in experiments such as finding potential drug molecules.

COVID-19 Impact

The COVID-19 pandemic had a minimal impact on the growth of the global non-animal alternative testing market in 2020. During the pandemic period, the pharmaceutical industry experienced a significant increase in the demand for medicines as people became more concerned about their health and well-being. Additionally, a number of drug developers resisted working in wet laboratories or coming in direct contact with animals and humans during pre-clinical drug testing. As a result, demand for non-animal alternative testing has increased significantly, promoting the rise of the market during the pandemic period.
 

Non-animal Alternative Testing market Trends

Pre-clinical studies give information on the safety and efficacy of a potential drug prior to testing it on humans. Such research involves proper preclinical models to compare it to the real-world population in order to obtain accurate results. Studies on animals are helping researchers discover regarding potential drug toxicity and dosing. As a result, the demand for drug research and development grows as well as the demand for animal models also increases, thereby fostering the market trends.
 

Further, PETA and Cruelty-Free International agencies are pressurising on the end-user industry to switch animal models to the alternate methods that ensure no animals are harmed, abused, or used in any way that affects the animal as well as people's sentiments. Hence, the awareness pertaining to non-animal alternative testing will propel the market outlook.
 

Non-animal Alternative Testing Market Analysis

Based on product type, the non-animal alternative testing market is segmented into organs-on-chips, cell lines, and tissue lines. The organ-on-chips segment dominated in 2022 with a market size of USD 872.9 million. The advantages of organ-on-chips (OOCs) over cell culture, animal models, and human clinical trials have attracted the interest of both the medical and pharmaceutical communities, that are working on producing personalised medicines.
 

For instance, in April 2020, researchers at the Massachusetts Institute of Technology (MIT) established a novel concept for Organs-on-a-Chip to investigate treatments for inflammatory diseases and ailments. Organs-on-a-chip are made up of millions of cells arranged on a platform to mimic the functioning of various organs and can be used as a tool for assessing and developing new treatments for complicated diseases without the usage of animals. Such benefits offered by OOCs is expected to propel the segmental growth.
 

Based on technology, the non-animal alternative testing market is segmented into cell culture technology, high throughput technology, molecular imaging, and omics technology. The cell culture technology segment accounted for USD 746.9 million in 2022. The increase is due to the fact that researchers frequently utilise cell culture technologies for analysing a large number of test results at once. Also, numerous pharmacological experiments are performed on eukaryotic cells, preferably human cells, that have been cultured under strictly monitored in vitro conditions to mimic the external environment of the human body.

Based on application, the non-animal alternative testing market is segmented into infectious diseases, immunological diseases, oncology, cardiovascular diseases, diabetes, genetic diseases, and neurological diseases. The infectious diseases segment dominated the market in 2022, with a CAGR of 7.8%. The dominance of segment is due to the fact that scientists estimate that more than 6 out of every 10 known infectious diseases in people can be spread from animals, and 3 out of every 4 new or emerging infectious diseases in people come from animals. Hence, the utilization of non-animal alternative testing for infectious diseases will accelerate the market growth.
 

Based on end-user, the non-animal alternative testing market is segmented into pharmaceutical companies, biotechnological companies, the cosmetics industry, research institutes & academics, contract research organization (CROs) and other end-users. The pharmaceutical industry segment is expected show 11% CAGR during the analysis period. The expansion is due to the pharmaceutical sector boosting its research and development efforts to provide new treatments for a variety of conditions. Also, rising disapproval to using animals for drug testing is further inspiring corporations to use in silico drug testing procedures to avoid any type of ethics concern. As a result, the market for non-animal alternative testing is predicted to increase at an exponential rate in the forecast period.
 

North America non-animal alternative testing market surpassed USD 653.8 million in 2022 with a growth rate of 8.2%. The region is dominating due to the presence of key players in these regions along with rising government support for non-animal alternative testing. Also, increasing prevalence of chronic diseases along with investment by key players in R&D activities to develop novel product is expected to supplement the market landscape.
 

Non-animal Alternative Testing Market Share

The global non-animal alternative testing industry comprises several players including :

• AlveoliX AG,
• MIMETAS
• MatTek Corporatio
• Emulate, Inc
• VITROCELL Systems GmbH
• Bio-Rad Laboratories, Inc.
• Hurel Corporation
• Evotec SE
• MB Research Laboratories
• TissUse GmbH.

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches, etc. to maintain a competitive edge in the industry.
 

Some of the recent industry developments:

• In September 2022, the National Medical Commission issued guidelines for pharmacology students in India, intended to promote the study of drug effects using simulation or computational models and replace the use of rats, rabbits, and guinea pigs. Such initiatives, alongside rapid technological innovation, will boost the usage of non-animal alternative testing in medical research.
   

The non-animal alternative testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product Type

• Organ-on-chips
• Cell lines
• Tissue lines

By Method

• Ex vivo testing
• Computer modelling
• Cellular assay
• Biochemical assay

By Technology

• Cell culture technology
• High throughput technology
• Molecular imaging
• Omics technology

By Application

• Infectious diseases
• Immunological diseases
• Oncology
• Cardiovascular diseases
• Diabetes
• Genetic diseases
• Neurological diseases

By End-use

• Pharmaceutical companies
• Biotechnological companies
• Research institutes and academics
• Contract research organization
• Other end-user

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa